Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study reported that a gemcitabine and pemetrexed regimen was moderately active in advanced NSCLC but did not offer an advantage over the paclitaxel and gemcitabine regimen and is not recommended for further evaluation.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

In this study, pemetrexed combined with cisplatin for advanced NSCLC treatment had similar efficacy to gemcitabine but resulted in significantly fewer adverse reactions.

In this study, a validated chromatographic method demonstrated the ability to simultaneously analyze gemcitabine and olaparib in pancreatic cancer tissues, supporting the advancement of pharmaceutical formulations combining these drugs, particularly for patients with BRCA mutations.

This study concluded that adding Kanglaite injection to gemcitabine and cisplatin chemotherapy for advanced non-small cell lung cancer improved response rates and reduced adverse side effects.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This study demonstrated that human plucked hairs can be used as a valuable biomarker to evaluate the pharmacodynamic responses of various chemotherapy agents ex vivo, supporting their potential use for assessing oncology drug target engagement prior to clinical studies.

This study identifies five compounds, including gemcitabine and methylene blue, that inhibit SADS-CoV and suggests their potential for developing antiviral drugs against future outbreaks.

This study found that spironolactone enhanced the effectiveness of non-DNA-damaging cancer drugs gemcitabine and osimertinib in cancer cell lines and a mouse xenograft model, likely by suppressing the anti-apoptotic protein survivin.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.

In this study, combining pemetrexed with cisplatin in non-small cell lung cancer patients improved immune function and had lower blood toxicity compared to cisplatin with gemcitabine, despite similar disease control rates and other side effects between the two treatment groups.

The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.

This scoping review identifies various pharmacological agents and five key mechanistic strategies being studied in vivo to mitigate multi-organ toxicity caused by cytarabine, with apraglutide and N-acetylcysteine highlighted as promising candidates for clinical application.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

In this systematic review, animal studies showed that cytarabine causes multi-organ toxicities, notably neurotoxicity, linked to oxidative stress and other mechanisms, though study quality raises concerns about reliability and translation to human outcomes.

This review discusses the management of adverse events associated with sacituzumab govitecan use in real-world settings and provides no new clinical results; it emphasizes practical strategies for clinicians treating breast cancer patients.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This article reports on lentiginosis observed within plaques of linear atrophoderma of Moulin and discusses its potential classification as a twin-spotting phenomenon but provides no new clinical research results.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This case study reports that a patient receiving Bojungikki-tang alongside chemotherapy showed improvement in hair loss despite ongoing treatment, suggesting a potential benefit for chemotherapy-induced alopecia.